AUTO.L -0.142BARC-O 0IPCO.TO -0.1TRI.TO -1.17C 0.42GFL.TO 0.25BRK.B 6.37PLUS 1.15
Eli Lilly & Co. (LLY)

NYSE:LLY

Eli Lilly & Co. (LLY)

1,279.14
+5.68 (0.45%)
as of Oct 26, 2026, 8:00:00 pm Market Closed.
225 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
PAST TOP PICK

Eli Lilly & Co.(LLY)

Apr 04, 2023
(A Top Pick Mar 18/20, Up 160%)

Health has been in a secular bear market for a decade and likely will remain there for another decade. However, LLY shares are toppy now around $360. You can't go wrong with this name or sector.

Photo of Hap (Robert) Sneddon FCSIHap (Robert) Sneddon FCSI
No
Unlock Rating
$355.15

Stock price when the opinion was issued

$1279.14

As of Oct 26, 2026. Market Closed.

biotechnologypharmaceutical
DON'T BUY

Eli Lilly & Co.(LLY)

Mar 21, 2023

Has done well. Their diabetes drug is effective for weight loss, which is pending approval, but would open a new market. She expects approval. Stock price reflects this approval though. Weight loss is a lucrative market given obesity levels around the world. The PE is too high for her, but may buy on a pullback.

Photo of Christine PooleChristine Poole
No
Unlock Rating
$331.10

Stock price when the opinion was issued

$1279.14

As of Oct 26, 2026. Market Closed.

biotechnologypharmaceutical
Unspecified

Eli Lilly & Co.(LLY)

Mar 13, 2023

The whole drug industry has been under pressure for the past 30 years and is having more and more trouble coming up with new drugs. R&D costs are increasing so he doesn't like the pharmaceutical industry in general. In response to a question regarding the currency component he doesn't feel it is an issue.

Photo of Lorne SteinbergLorne SteinbergUnlock Rating
$324.49

Stock price when the opinion was issued

$1279.14

As of Oct 26, 2026. Market Closed.

biotechnologypharmaceutical
Unspecified

Eli Lilly & Co.(LLY)

Feb 27, 2023

It has outperformed the sector. The technicals are OK but but it is not in a great space. He owns some but would not buy more at this time.

Photo of David BurrowsDavid Burrows
Owned
Unlock Rating
N/A

Stock price when the opinion was issued

$1279.14

As of Oct 26, 2026. Market Closed.

biotechnologypharmaceutical
BUY

Eli Lilly & Co.(LLY)

Jan 27, 2023
It reports Thursday. He thinks their new drug will be the biggest seller of all time. He owns a lot of shares.
Photo of Jim Cramer - Mad MoneyJim Cramer - Mad Money
Owned
Unlock Rating
$342.10

Stock price when the opinion was issued

$1279.14

As of Oct 26, 2026. Market Closed.

biotechnologypharmaceutical
BUY

Eli Lilly & Co.(LLY)

Jan 25, 2023
Just announced a $450 million commitment to develop a promising diabetes drug that helps weight loss. The stock still has legs.
Photo of Jim Cramer - Mad MoneyJim Cramer - Mad Money
Owned
Unlock Rating
$348.60

Stock price when the opinion was issued

$1279.14

As of Oct 26, 2026. Market Closed.

biotechnologypharmaceutical
PAST TOP PICK

Eli Lilly & Co.(LLY)

Jan 06, 2023
(A Top Pick Mar 14/22, Up 34%) Great company with high demand product (insulin). Building R&D portfolio that is on cutting edge. New drugs in the pipeline that will be approved. Weight loss products look promising.
Photo of David FingoldDavid Fingold
Owned
Unlock Rating
$362.94

Stock price when the opinion was issued

$1279.14

As of Oct 26, 2026. Market Closed.

biotechnologypharmaceutical
PARTIAL BUY

Eli Lilly & Co.(LLY)

Dec 09, 2022
Owns a big positions. Is a conservative company that doesn't hype itself or drugs which turns off some investors. Amazing diabetes, obesity and potentially Alzheimer drugs. Are having an analyst meeting on Tuesday, so wait after that to buy.
Photo of Jim Cramer - Mad MoneyJim Cramer - Mad Money
Owned
Unlock Rating
$363.79

Stock price when the opinion was issued

$1279.14

As of Oct 26, 2026. Market Closed.

biotechnologypharmaceutical
TOP PICK

Eli Lilly & Co.(LLY)

Dec 07, 2022
Super-excited about long-term prospects from new products, which could lead to 40% sales growth by 2025-26. These products will also increase margins. Biggest opportunity is within weight loss, initial results of a 3-year study are looking good, targeting obesity as well as its complications. Not cheap, but will continue to outperform. Yield is 1.05%. (Analysts’ price target is $381.39)
Photo of Michael Hakes - CFA, MBAMichael Hakes - CFA, MBA
Owned
Unlock Rating
$373.50

Stock price when the opinion was issued

$1279.14

As of Oct 26, 2026. Market Closed.

biotechnologypharmaceutical
BUY ON WEAKNESS

Eli Lilly & Co.(LLY)

Oct 04, 2022
Allan Tong’s Discover Picks You could then take that money and put it in Eli Lilly. There’s potential in LLY stock’s own Alzheimer’s drug. Also, the street is putting its hopes into LLY’s weight-loss drug, Mounjaro, when it starts selling in two or three years. After all, diabetes as at an all-time high in America. One analyst envisioned $25 billion in peak sales, outstripping AbbVie‘s Humira which has topped $20.7 billion. However, the street is getting a little ahead of itself, since the FDA has approved Mounjaro for glycemic control in T2D patients, and LLY still needs to submit the drug as a treatment for weight-loss. Read Mixed bag of 3 Defensive Stocks for our full analysis.
Photo of Stockchase DiscoverStockchase DiscoverUnlock Rating
$329.89

Stock price when the opinion was issued

$1279.14

As of Oct 26, 2026. Market Closed.

biotechnologypharmaceutical
BUY ON WEAKNESS

Eli Lilly & Co.(LLY)

Sep 21, 2022
A big holding. He almost bought more now. The drug stocks can go lower, but the future for Eli's weight-loss drug is huge and could be good for their Alzheimer's drug. Buy more when it breaks $280s.
Photo of Jim Cramer - Mad MoneyJim Cramer - Mad Money
Owned
Unlock Rating
$296.48

Stock price when the opinion was issued

$1279.14

As of Oct 26, 2026. Market Closed.

biotechnologypharmaceutical
BUY

Eli Lilly & Co.(LLY)

Aug 24, 2022
Plenty of upside from its improved diabetes and obesity drug. Their Alzheimer's drug has potential As a drugmaker, it won't be hostage to a recession. Drugs will keep selling.
Photo of Jim Cramer - Mad MoneyJim Cramer - Mad Money
Owned
Unlock Rating
$318.87

Stock price when the opinion was issued

$1279.14

As of Oct 26, 2026. Market Closed.

biotechnologypharmaceutical
BUY

Eli Lilly & Co.(LLY)

Aug 19, 2022
Around 15% topline growth. Likes healthcare, great fundamentals and 23% expected EPS growth.
Photo of Rob Sechan, Managing Partner, New Edge CapitalRob Sechan, Managing Partner, New Edge CapitalUnlock Rating
$324.57

Stock price when the opinion was issued

$1279.14

As of Oct 26, 2026. Market Closed.

biotechnologypharmaceutical
BUY

Eli Lilly & Co.(LLY)

Aug 10, 2022
Focusing on its diabetes and weight loss drug. The weight loss drug could be one of the biggest drugs of all time, when it starts selling in the next 2-3 years.
Photo of Jamie Murray Jamie Murray
Owned
Unlock Rating
$302.93

Stock price when the opinion was issued

$1279.14

As of Oct 26, 2026. Market Closed.

biotechnologypharmaceutical
BUY

Eli Lilly & Co.(LLY)

Jul 11, 2022
It seems cheap, because they have 4-7 billion-dollar drugs in their pipeline. So, estimates will have to move up dramatically and the PE will be lower. Therefore, the stock doesn't look as expensive as it seems.
Photo of Jim Cramer - Mad MoneyJim Cramer - Mad MoneyUnlock Rating
$331.07

Stock price when the opinion was issued

$1279.14

As of Oct 26, 2026. Market Closed.

biotechnologypharmaceutical
Showing 151 to 165 of 223 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

GBCI 1.19$49
BB.TO 0.43$12.89
TMO 11.07$684.89
AMAT 10.35$387.59
CCOM.TO -0.1$20.14

Today's Top Picks

AUTO.L -0.142$5.28
BARC-O 0$
IPCO.TO -0.1$40.19
TRI.TO -1.17$171.24
C 0.42$121.04

Popular Articles

Latest Sell Signals

QNNT 0$
ZCOM.CN 0$
GIS -0.69$33.7
SDE.TO -0.12$14.75
TD.TO 1.29$175.76

Most Recent Experts

Jim Cramer - Mad Money

Jim Cramer - Mad Money

CNBC

Larry Berman CFA, CMT, CTA

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

Cole Smead

Cole Smead

Smead Capital Management

Stephanie Link, Chief investment strategist, Hightower

Stephanie Link, Chief investment strategist, Hightower

Hightower

Jason Snipe, CIO, Odyssey Capital Advisors

Jason Snipe, CIO, Odyssey Capital Advisors

Odyssey Capital Advisors

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica
The ultimate 360° Tracker Your financial life in one place, automatically

You may also like